Therapies that disrupt the pathway targeting IFN-γ, the IFN-γ receptor, the downstream signal JAK-STAT pathway, CXCL10 and its receptor CXCR3 have been some of the most promising in vitiligo management and may become the first to be approved. The gene discussed is CXCL10; the disease is vitiligo.